目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
TABLE 1 BIOSIMILARS MARKET: INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 LIMITATIONS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 31)
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.2 SECONDARY DATA
FIGURE 2 SECONDARY SOURCES
2.3 PRIMARY DATA
FIGURE 3 KEY DATA FROM PRIMARY SOURCES
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.5 MARKET ESTIMATION METHODOLOGY
2.5.1 BOTTOM-UP APPROACH
2.5.2 TOP-DOWN APPROACH
FIGURE 6 TOP-DOWN APPROACH
FIGURE 7 BIOSIMILARS MARKET: FINAL MARKET SIZE (USD BILLION)
2.6 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
2.7 INSIGHTS FROM PRIMARIES
FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
2.8 RESEARCH ASSUMPTIONS
2.9 LIMITATIONS
2.10 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. - 41)
FIGURE 9 BIOSIMILARS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 10 BIOSIMILARS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 11 BIOSIMILARS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 44)
4.1 BIOSIMILARS MARKET OVERVIEW
FIGURE 12 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT AND COUNTRY (2020)
FIGURE 13 INSULIN HELD THE LARGEST SHARE OF THE NORTH AMERICAN BIOSIMILARS MARKET IN 2020
4.3 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET
FIGURE 14 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing demand for biosimilar drugs due to their cost-effectiveness
5.2.1.2 Rising geriatric population and the increasing incidence of chronic diseases
FIGURE 16 GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION)
FIGURE 17 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
5.2.1.3 Abbreviated regulatory approval process and concept of interchangeability
FIGURE 18 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS
5.2.2 RESTRAINTS
5.2.2.1 Complexities in manufacturing
5.2.2.2 Resistance from biologics manufacturers
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Patent expiry of blockbuster biologics and research on new indications
TABLE 2 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
5.2.4 CHALLENGES
5.2.4.1 Excess competition
5.2.5 TRENDS
5.2.5.1 Collaborations for biosimilar research and clinical trials
TABLE 3 MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017-2020)
5.3 COVID-19 IMPACT ANALYSIS
5.4 TECHNOLOGY ANALYSIS
TABLE 4 COMPARISON OF ORIGINAL BIOLOGICS WITH BIOSIMILARS
TABLE 5 GENERIC DRUGS VS. BIOSIMILARS
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS FOR BIOSIMILARS
5.6 ECOSYSTEM MARKET MAP
FIGURE 20 ECOSYSTEM MARKET MAP FOR BIOSIMILARS
5.7 SUPPLY CHAIN ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PORTER’S FIVE FORCES: IMPACT ANALYSIS ON THE BIOSIMILARS MARKET
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY LANDSCAPE
TABLE 7 REGULATORY LANDSCAPE FOR THE BIOSIMILARS MARKET

6 BIOSIMILARS MARKET, BY PRODUCT (Page No. - 63)
6.1 INTRODUCTION
FIGURE 21 BIOSIMILARS APPROVED IN THE US, EUROPE, AND CHINA, BY TYPE
TABLE 8 BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
6.2 MONOCLONAL ANTIBODIES
TABLE 9 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 10 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2019-2026 (USD MILLION)
6.2.1 INFLIXIMAB
6.2.1.1 Infliximab accounted for the largest share of the monoclonal antibodies market
TABLE 11 BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2019-2026 (USD MILLION)
6.2.2 TRASTUZUMAB
6.2.2.1 Rising incidence of cancer to drive market growth
TABLE 12 BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2019-2026 (USD MILLION)
6.2.3 RITUXIMAB
6.2.3.1 Rising incidence of autoimmune diseases and cancer are key drivers for market growth
TABLE 13 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2019-2026 (USD MILLION)
6.2.4 ADALIMUMAB
6.2.4.1 Adalimumab to register the highest CAGR in the monoclonal antibodies market
TABLE 14 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2019-2026 (USD MILLION)
6.2.5 OTHER MONOCLONAL ANTIBODIES
TABLE 15 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2019-2026 (USD MILLION)
6.3 INSULIN
6.3.1 INCREASING INCIDENCE OF DIABETES TO SUPPORT MARKET GROWTH
TABLE 16 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2019-2026 (USD MILLION)
6.4 GRANULOCYTE COLONY-STIMULATING FACTOR
6.4.1 G-CSF IS USED TO TREAT CANCER PATIENTS WITH NEUTROPENIA OCCURRING AFTER CHEMOTHERAPY
TABLE 17 LIST OF APPROVED BIOSIMILARS FOR G-CSF
TABLE 18 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2019-2026 (USD MILLION)
6.5 ERYTHROPOIETIN
6.5.1 RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
TABLE 19 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
TABLE 20 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,2019-2026 (USD MILLION)
6.6 RECOMBINANT HUMAN GROWTH HORMONE
6.6.1 MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
TABLE 21 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,BY REGION, 2019-2026 (USD MILLION)
6.7 ETANERCEPT
6.7.1 APAC TO WITNESS THE HIGHEST GROWTH IN THE ETANERCEPT MARKET DURING THE FORECAST PERIOD
TABLE 22 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION,2019-2026 (USD MILLION)
6.8 FOLLITROPIN
6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET GROWTH
TABLE 23 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2019-2026 (USD MILLION)
6.9 TERIPARATIDE
6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 24 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2019-2026 (USD MILLION)
6.10 INTERFERONS
6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
TABLE 25 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2019-2026 (USD MILLION)
6.11 ENOXAPARIN SODIUM
6.11.1 WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
TABLE 26 BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION, 2019-2026 (USD MILLION)
6.12 GLUCAGON
6.12.1 SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
TABLE 27 BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2019-2026 (USD MILLION)
6.13 CALCITONIN
6.13.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO DRIVE MARKET GROWTH
TABLE 28 BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2019-2026 (USD MILLION)

7 BIOSIMILARS MARKET, BY INDICATION (Page No. - 79)
7.1 INTRODUCTION
TABLE 29 BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
7.2 ONCOLOGY
7.2.1 RISING BURDEN OF CANCER TO DRIVE THE DEMAND FOR BIOSIMILARS
FIGURE 22 CANCER CASES, BY TYPE, 2020 (MILLION)
FIGURE 23 DEATHS DUE TO CANCER, BY TYPE, 2020 (MILLION)
TABLE 30 BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2018-2020
FIGURE 24 ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY, 2012-2020
TABLE 31 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2019-2026 (USD MILLION)
7.3 INFLAMMATORY & AUTOIMMUNE DISEASES
7.3.1 CHANGES IN LIFESTYLE AND ENVIRONMENTAL CONDITIONS HAVE INCREASED THE INCIDENCE OF INFLAMMATORY & AUTOIMMUNE DISEASES
TABLE 32 BIOSIMILARS MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASES, BY REGION, 2019-2026 (USD MILLION)
7.4 CHRONIC DISEASES
7.4.1 HIGH BURDEN OF CVD & DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
TABLE 33 BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES, 2018-2020
TABLE 34 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2019-2026 (USD MILLION)
7.5 BLOOD DISORDERS
7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS HAS INCREASED THE DEMAND FOR BIOSIMILARS FOR THIS INDICATION SEGMENT
TABLE 35 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2019-2026 (USD MILLION)
7.6 GROWTH HORMONE DEFICIENCY
7.6.1 GROWING USE OF BIOSIMILARS FOR THE TREATMENT OF THIS MEDICAL CONDITION TO SUPPORT MARKET GROWTH
TABLE 36 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2026 (USD MILLION)
7.7 INFECTIOUS DISEASES
7.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES IS EXPECTED TO BE THE HIGHEST IN THE ASIA PACIFIC
TABLE 37 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD MILLION)
7.8 OTHER INDICATIONS
TABLE 38 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2019-2026 (USD MILLION)

8 BIOSIMILARS MARKET, BY REGION (Page No. - 90)
8.1 INTRODUCTION
FIGURE 25 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 39 BIOSIMILARS MARKET, BY REGION, 2019-2026 (USD MILLION)
8.2 EUROPE
TABLE 40 LIST OF BIOSIMILARS APPROVED IN EUROPE
FIGURE 26 EUROPE: BIOSIMILARS MARKET SNAPSHOT
TABLE 41 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 42 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 43 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 44 EUROPE: BIOSIMILARS MARKET, BY INDICATION,2019-2026 (USD MILLION)
8.2.1 UK
8.2.1.1 The UK holds the largest share of the biosimilars market in Europe
TABLE 45 LIST OF BIOSIMILARS IN THE UK
TABLE 46 UK: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 47 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 48 UK: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.2.2 FRANCE
8.2.2.1 Rising geriatric population will drive market growth
TABLE 49 FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 50 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 51 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.2.3 GERMANY
8.2.3.1 Presence of a favorable pricing system has supported biosimilar adoption in Germany
TABLE 52 GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 53 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 54 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.2.4 ITALY
8.2.4.1 Rising geriatric population in Italy will support the adoption of biosimilars in the country
TABLE 55 ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 56 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 57 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.2.5 SPAIN
8.2.5.1 Patient incentives to promote biosimilar use is a key growth driver for the biosimilars market in Spain
TABLE 58 SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 59 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 60 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.2.6 REST OF EUROPE
TABLE 61 ROE: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 62 ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 63 ROE: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.3 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
TABLE 64 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 65 ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 66 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 67 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.3.1 INDIA
8.3.1.1 India held the largest share of the APAC biosimilars market
TABLE 68 BIOSIMILARS APPROVED AND MARKETED IN INDIA
TABLE 69 INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 70 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 71 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.3.2 CHINA
8.3.2.1 China is the fastest-growing market for biosimilars in the APAC
TABLE 72 BIOSIMILARS APPROVED IN CHINA
TABLE 73 CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 74 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 75 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.3.3 SOUTH KOREA
8.3.3.1 Favorable government initiatives to drive the market in South Korea
TABLE 76 LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
TABLE 77 SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 78 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 79 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.3.4 JAPAN
8.3.4.1 Large geriatric population in the country to drive market growth
TABLE 80 LIST OF BIOSIMILARS APPROVED IN JAPAN
TABLE 81 JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 82 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 83 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.3.5 AUSTRALIA
8.3.5.1 Incremental changes in biosimilar regulations and increasing incidence of chronic diseases to drive market growth
TABLE 84 LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
TABLE 85 AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 86 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 87 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.3.6 REST OF ASIA PACIFIC
TABLE 88 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
TABLE 89 LIST OF BIOSIMILARS APPROVED IN MALAYSIA
TABLE 90 LIST OF BIOSIMILARS APPROVED IN SINGAPORE
TABLE 91 ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 92 ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 93 ROAPAC: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.4 NORTH AMERICA
TABLE 94 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 95 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 96 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 97 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.4.1 US
8.4.1.1 The US dominates the North American biosimilars market
TABLE 98 LIST OF BIOSIMILARS APPROVED IN THE US
TABLE 99 US: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 100 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 101 US: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.4.2 CANADA
8.4.2.1 Favorable government initiatives to support market growth
TABLE 102 LIST OF BIOSIMILARS APPROVED IN CANADA
TABLE 103 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 104 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 105 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
TABLE 106 LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
TABLE 107 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 108 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 109 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,2019-2026 (USD MILLION)
8.6 MIDDLE EAST AND AFRICA
8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
TABLE 110 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 111 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 112 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. - 146)
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACH
FIGURE 28 KEY DEVELOPMENTS OF MAJOR PLAYERS, JANUARY 2018-AUGUST 2021
9.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
FIGURE 29 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST THREE YEARS
9.4 MARKET SHARE ANALYSIS
FIGURE 30 GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
9.5 COMPANY EVALUATION QUADRANT
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 31 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2020
9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
9.6.1 PROGRESSIVE COMPANIES
9.6.2 STARTING BLOCKS
9.6.3 RESPONSIVE COMPANIES
9.6.4 DYNAMIC COMPANIES
FIGURE 32 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
9.7 COMPETITIVE BENCHMARKING
9.7.1 COMPANY PRODUCT FOOTPRINT
9.7.2 COMPANY INDICATION FOOTPRINT
9.7.3 COMPANY REGIONAL FOOTPRINT
9.8 GROWTH STRATEGIES ADOPTED BY EMERGING AND KEY PLAYERS
9.8.1 PRODUCT LAUNCHES & APPROVALS
9.8.2 DEALS
9.8.3 OTHER DEVELOPMENTS

10 COMPANY PROFILES (Page No. - 159)
10.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOVARTIS AG
TABLE 113 NOVARTIS AG: BUSINESS OVERVIEW
FIGURE 33 SANDOZ: COMPANY SNAPSHOT (2020)
10.1.2 PFIZER INC.
TABLE 114 PFIZER INC: BUSINESS OVERVIEW
FIGURE 34 PFIZER INC.: COMPANY SNAPSHOT (2020)
10.1.3 DR. REDDY’S LABORATORIES LTD.
TABLE 115 DR. REDDY’S LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2020)
10.1.4 AMGEN INC.
TABLE 116 AMGEN INC.: BUSINESS OVERVIEW
FIGURE 36 AMGEN INC.: COMPANY SNAPSHOT (2020)
10.1.5 ELI LILLY AND COMPANY
TABLE 117 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
FIGURE 37 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)
10.1.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 118 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)
10.1.7 FRESENIUS SE & CO. KGAA
TABLE 119 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
FIGURE 39 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2020)
10.1.8 STADA ARZNEIMITTEL AG
TABLE 120 STADA ARZNEIMITTEL: BUSINESS OVERVIEW
FIGURE 40 STADA ARZNEIMITTEL: COMPANY SNAPSHOT (2020)
10.1.9 BOEHRINGER INGELHEIM
TABLE 121 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
FIGURE 41 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020)
10.1.10 GEDEON RICHTER PLC
TABLE 122 GEDEON RICHTER PLC: BUSINESS OVERVIEW
FIGURE 42 GEDEON RICHTER PLC: COMPANY SNAPSHOT (2020)
10.1.11 CELLTRION
TABLE 123 CELLTRION: BUSINESS OVERVIEW
FIGURE 43 CELLTRION: COMPANY SNAPSHOT (2020)
10.1.12 SAMSUNG BIOLOGICS
TABLE 124 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
FIGURE 44 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2020)
10.1.13 COHERUS BIOSCIENCES
TABLE 125 COHERUS BIOSCIENCES: BUSINESS OVERVIEW
FIGURE 45 COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2020)
10.1.14 BIOCON LIMITED
TABLE 126 BIOCON LIMITED: BUSINESS OVERVIEW
FIGURE 46 BIOCON LIMITED: COMPANY SNAPSHOT (2020)
10.1.15 VIATRIS
TABLE 127 VIATRIS: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 AMEGA BIOTECH
TABLE 128 AMEGA BIOTECH: BUSINESS OVERVIEW
10.2.2 APOTEX INC.
TABLE 129 APOTEX INC.: BUSINESS OVERVIEW
10.2.3 BIOCAD
TABLE 130 BIOCAD: BUSINESS OVERVIEW
10.2.4 MABXIENCE
TABLE 131 MABXIENCE: BUSINESS OVERVIEW
10.2.5 PROBIOMED S.A. DE C.V.
TABLE 132 PROBIOMED: BUSINESS OVERVIEW
10.2.6 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
TABLE 133 FUJIFILM KYOWA KIRIN BIOLOGICS: BUSINESS OVERVIEW
10.2.7 INTAS PHARMACEUTICALS LTD.
TABLE 134 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
10.2.8 THERAMEX
TABLE 135 THERAMEX: BUSINESS OVERVIEW
10.2.9 RELIANCE LIFE SCIENCES
TABLE 136 RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
10.2.10 KASHIV BIOSCIENCES
TABLE 137 KASHIV BIOSCIENCES: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX (Page No. - 222)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS